Taking a Deep Dive Into the Role of IL-17 Inhibitors for Psoriasis: What do PAs and NPs Need to Know? FCPANP23 Seminar-in-Depth
Seminar-in-Depth: Taking a Deep Dive Into the Role of IL-17 Inhibitors for Psoriasis: What do PAs and NPs Need to Know?
This activity is supported by an educational grant from UCB.
At the completion of this activity, participants should be better able to:
Identify the role of IL-17A and IL-17F inhibitors across multiple disease pathways and how therapies target this pathway
Discuss the benefit-risk profiles of IL-17 inhibitors for the management of psoriasis
Describe strategies on how to work as a multidisciplinary team to individualize patient care with IL-17 inhibitors
April Armstrong, MD, MPH
Chief, Division of Dermatology
David Geffen School of Medicine at UCLA
Los Angeles, CA
David Pariser, MD
Professor of Dermatology
Eastern Virginia Medical School
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of University of Nevada and CMEsquared. The University of Nevada is accredited by the ACCME to provide continuing medical education for physicians.
Credit Designation Statement
The University of Nevada designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Disclosures & Disclaimers
Disclosures are as follows:
Grant/Research Support: BMS, Leo, UCB, Lilly, Dermavant, Dermira, Pfizer, AbbVie, ASLAN, BI, EPI, Incyte, Janssen
Consultant: Lilly, Novartis, Ortho, SUN, Dermavant, Dermira, Sanofi Regeneron, Pfizer, Parexel
Dr. Pariser has disclosed that he has no relevant financial relationships with any Ineligible company in the past 24 months.
The University of Nevada discloses that all relevant conflicts have been satisfactorily mitigated.